Physician profile
Devon G John
NPI 1932196862
$1,217.59
in general payments reported to CMS, 2019-2025
8 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.82 · 2021: $216 · 2022: $229 · 2023: $240 · 2024: $54.14 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $331.15 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Abbvie INC. | $294.63 | 2023-2024 | |
| Allergan, INC. | $293.61 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $111.45 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $25.88 | 2022 | |
| Gilead Sciences, INC. | $25.05 | 2025 | |
| Veloxis Pharmaceuticals, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.